NTRA
NASDAQ · Biotechnology
Natera Inc
$322.10
+56.72 (+21.37%)
Financial Highlights (FY 2026)
Revenue
2.37B
Net Income
-214,247,722
Gross Margin
64.7%
Profit Margin
-9.0%
Rev Growth
+41.1%
D/E Ratio
0.05
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 64.7% | 64.7% | 37.3% | 37.3% |
| Operating Margin | -13.4% | -12.1% | 17.8% | 21.3% |
| Profit Margin | -9.0% | -8.6% | 17.1% | 19.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.37B | 1.68B | 5.13B | 5.06B |
| Gross Profit | 1.54B | 1.09B | 1.91B | 1.89B |
| Operating Income | -319,009,597 | -203,421,168 | 914.70M | 1.08B |
| Net Income | -214,247,722 | -136,618,215 | 875.75M | 965.00M |
| Gross Margin | 64.7% | 64.7% | 37.3% | 37.3% |
| Operating Margin | -13.4% | -12.1% | 17.8% | 21.3% |
| Profit Margin | -9.0% | -8.6% | 17.1% | 19.1% |
| Rev Growth | +41.1% | +41.1% | +14.5% | +4.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.02B | 1.02B | 9.62B | 10.44B |
| Total Equity | 21.65B | 21.65B | 7.95B | 7.98B |
| D/E Ratio | 0.05 | 0.05 | 1.21 | 1.31 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -317,213,277 | -213,513,258 | 1.33B | 1.35B |
| Free Cash Flow | — | — | 778.23M | 1.13B |